NextCure, Inc.
No enriched coverage for $NXTC in the last 7 days.
No SEC Form 4 filings for $NXTC in the last 30 days.
See all $NXTC insider activity →NextCure, Inc. (NXTC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NEXTCURE, INC. ) ) ) C.A. No. 2026-____-_____ verified petition for relief pursuant to 8 del. c. § 205 Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned co
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Compan
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
Recent NXTC coverage spans insider activity, corporate actions and mergers & acquisitions.
Potential validation could clear the reverse split, supporting the pending business combination; denial may delay or derail the deal and pressure the stock.
The lease termination removes future rent obligations but incurs a modest cash outflow.
The merger announcement is a valuation and corporate-action catalyst for NextCure, with terms likely to drive trading.
This is an insider-related indirect sale with no 10b5-1 plan stated, but it is not a fundamental company disclosure.
Deal mechanics and timing can re-rate NXTC on deal certainty, funding structure, and post-merger pipeline value.
AlphAI scores every news story that mentions NXTC with an AI model for sentiment and relevance, and aggregates insider trades from NextCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NEXTCURE, INC. ) ) ) C.A. No. 2026-____-_____ verified petition for relief pursuant to 8 del. c. § 205 Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned co
2 min readNextCure, Inc. (NXTC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Compan
1 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readSimcere Zaiming, Inc. sold 30,000 indirectly-held shares of NextCure, Inc. (NXTC) at $6.16 ($0.18M total) on 2026-08-10.
2 min readRTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.
4 min readNextCure (NXTC) reported Q2 2026 net loss of $14.9M, narrower than $26.8M a year earlier, with lower R&D and G&A expenses. It also recorded $5.1M asset impairments. NextCure said its all-stock merger with Avere Therapeutics is expected to close in H2 2026, with the combined firm trading as AVRX and Avere pursuing about $320M gross private financing.
5 min readNextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results – Announced Proposed Merger with Avere Therapeutics – Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, MD –
6 min readADAR1 Capital Management, LLC purchased 329,153 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.93 ($4.80–$5.00, $1.62M total) across 9 trades over 2026-07-30 to 2026-07-31.
2 min readADAR1 Capital Management, LLC purchased 17,608 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.98 ($4.95–$5.00) across 4 trades over 2026-07-27 to 2026-07-29.
2 min readBiotech stocks rose Tuesday. NextCure (NXTC) jumped over 200% on a definitive all-stock merger with Avere Therapeutics, expected to close in 2H 2026, with the combined firm trading as AVRX. Basel Medical (BMGL) gained 26% after regaining Nasdaq bid-price compliance. Outlook Therapeutics (OTLK) rose 11% ahead of an FDA decision on July 29, 2026. Other gainers included DYAI, NUWE, ATAI, and QNCX.
2 min read
